Press Release: AGILON HEALTH CLASS ACTION REMINDER: Bragar Eagel & Squire, P.C. Reminds Agilon Health Stockholders to Contact the Firm Regarding Their Rights
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Agilon (AGL) To Contact Him Directly To Discuss Their Options If you purchased or acquired Agilon securities between February 26, 2025 and August 4, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Melissa Forunato…
MONACO, June 26, 2026 (GLOBE NEWSWIRE) -- Crypto news today is turning toward AlphaPepe as Binance listing speculation grows after the project announced two CEX partnerships before launch. AlphaPepe has already revealed Azbit and BiFinance, while the presale has now raised $1.75 million, passed 9,600 holders, and reached a current token price of $0.01993.
LOS ANGELES, June 26, 2026 (GLOBE NEWSWIRE) -- PrivacyHawk, the transparency-first data privacy company, today announced the general availability of PrivacyHawk Enterprise — a first-of-its-kind solution that identifies and eliminates the shadow IT accounts, abandoned SaaS subscriptions, and forgotten third-party services quietly exposing organizations to breach risk.
London, United Kingdom, June 26, 2026 (GLOBE NEWSWIRE) -- As artificial intelligence continues to reshape global financial markets, AI trading bots are rapidly becoming essential tools for retail investors participating in forex, cryptocurrency, and CFD markets. Today, fintech platform QuantRate announced a major upgrade to its global trading access infrastructure, designed to improve automated trading execution…
LOS ANGELES, June 26, 2026 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.
SAN DIEGO, June 26, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced positive five-year data from its ongoing HOPE-2 Open-Label Extension (OLE) study of Deramiocel, the Company’s lead cell therapy candidate for Duchenne Muscular Dystrophy (DMD). The data will be presented…
Related Product Search/Búsqueda de productos relacionados
Visit Our New Print-On-Demand Stores On Printify and Zazzle
Featured Guest Posts
Contact Men's Journal Men's Journal is a rugged and refined lifestyle adventure travel, food, and drink magazine. Get in touch at mensjournalcompanies@gmail.com to find out how they can help you reach everyday, affluent, and adventure-seeking consumers on Men's Journal.
IT Career News Microsoft Exam Dropshipping Guide E-commerce Guide Career Exam Study Automotive Technology Travel Eastern Europe Boat Loan Calculator
Notices
Flying The Web For Deals Weather Alerts End Windows Support Dates Paid Featured Guest Posts List